BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11508932)

  • 21. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
    Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
    J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
    Northup JK; Gadre SA; Ge Y; Lockhart LH; Velagaleti GV
    Eur J Haematol; 2007 Feb; 78(2):152-6. PubMed ID: 17313561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
    Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
    J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
    Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials for malignant lymphoma in Japan.
    Tobinai K; Hotta T
    Jpn J Clin Oncol; 2004 Jul; 34(7):369-78. PubMed ID: 15342663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients.
    Addeo R; Caraglia M; Costanzo R; Faiola V; Montella L; Abbruzzese A; Del Prete S
    Oncol Rep; 2004 Jul; 12(1):135-40. PubMed ID: 15201974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Economopoulos T; Fountzilas G; Pavlidis N; Kalantzis D; Papageorgiou E; Christodoulou C; Hamilos G; Nicolaides C; Dimopoulos M
    Hematol J; 2003; 4(2):110-5. PubMed ID: 12750729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
    Ise M; Sakai C; Kumagai K
    Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
    Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
    J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab: new indication. In aggressive non Hodgkin lymphoma: benefits must be confirmed.
    Prescrire Int; 2003 Aug; 12(66):125-6. PubMed ID: 12906019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
    J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma.
    Swaneveld FH; van Vugt RM; de Boer JP; Dijkmans BA; Lems WF
    Clin Rheumatol; 2008 Feb; 27(2):249-51. PubMed ID: 17660934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
    Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
    Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
    J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
    Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
    In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
    Olivieri A; Lucesole M; Capelli D; Gini G; Montanari M; Candela M; Troiani E; Scortechini I; Poloni A; Leoni P
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.